Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Tarfah Al-WarhiAhmed M El KerdawyMohamed A SaidAmgad AlbohyZainab M ElsayedNada AljaeedEslam B ElkaeedWagdy M EldehnaHatem A Abdel-AzizMiral A AbdelmoazPublished in: Drug design, development and therapy (2022)
in the active site of EGFR revealed a common binding pattern similar to that of erlotinib which involves the accommodation of the 1,3 thiazol-4-one ring and pyrazoline ring of target compounds in the binding region of erlotinib's quinazoline ring and anilino moiety.